Nuvation Bio Soars 8.72% on Positive Lung Cancer Drug Data

On September 8, 2025, Nuvation Bio's stock price surged by 8.72% in pre-market trading, reflecting significant investor interest and optimism surrounding the company's recent developments.

Nuvation Bio recently announced updated results from its pivotal Phase 2 TRUST-I and TRUST-II studies, which evaluated IBTROZI for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). The findings demonstrated sustained durability of responses in both studies, with TKI-naïve patients in TRUST-I achieving a median progression-free survival of 44.6 months. More than half of TKI-naïve patients in TRUST-II were still progression-free at the data cut-off, highlighting the drug's efficacy and durability.

The studies also showed a favorable safety and tolerability profile for IBTROZI, with manageable adverse events. These results are part of one of the largest global clinical trial programs in ROS1-positive NSCLC to date, involving over 300 patients. The positive outcomes from these studies have further supported the recent approval of IBTROZI in the U.S., providing an important new treatment option for patients with this form of lung cancer.